Repligen (RGEN) Misses Q2 EPS by 2c
Get Alerts RGEN Hot Sheet
Price: $168.53 +0.55%
Revenue Growth %: +9.4%
Financial Fact:
Product revenue: 24.68M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +9.4%
Financial Fact:
Product revenue: 24.68M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.16, $0.02 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $47.7 million versus the consensus estimate of $46.08 million.
GUIDANCE:
Repligen sees FY2018 EPS of $0.69-$0.73, versus the consensus of $0.71. Repligen sees FY2018 revenue of $185-190 million, versus the consensus of $185.35 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
- BMO Capital Starts American Eagle Outfitters (AEO) at Market Perform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share